CoreMap, Inc. is a medical technology company headquartered in Winooski, Vermont, developing advanced diagnostic and mapping tools to improve the treatment of atrial fibrillation.
Subscribe to see CoreMap, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CoreMap, Inc. is a healthcare company headquartered in United States. It has raised at least $75.3M across the 6 funding rounds on record. Its most recent funding round raised $35.5M in June 2026. Xcout tracks 4 named people at CoreMap, Inc., including Sarah O. Kalil (CEO).
At least $75.3M raised across the 6 rounds on record. The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $35.5M | — | |
| SEC Form D filing | $6.8M | — | |
| Series C | $23.2M | 1 named | |
| SEC Form D filing | $8.9M | — | |
| SEC Form D filing | $500,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of CoreMap, Inc.'s closest competitors — see the full list of competitors and alternatives →
Cortex, Inc. is a medical technology company based in Menlo Park, California. The company specializes in the medical device sector, focusing specifically on innovative products for the diagnosis and treatment of atrial arrhythmias.
CathVision is a medical technology company founded in 2013 and headquartered in Copenhagen, Denmark, specializing in electrophysiology (EP) recording technologies and developer of the FDA-cleared ECGenius System.
CoraVie Medical is an early-stage medical device company headquartered in Minneapolis, Minnesota, transforming blood pressure monitoring with a breakthrough implantable solution.
CardiaCare, also known as StimCardio Medical, is a medical device company headquartered in Rehovot, Israel, advancing wearable neuromodulation therapy for atrial fibrillation.
CorAssist Cardiovascular Ltd. was a clinical-stage medical device company based in Haifa, Israel, focused on developing therapeutic products for treating heart failure with preserved ejection fraction and diastolic heart failure. The company ceased operations in December 2022.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.